FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W107292743> ?p ?o ?g. }

• W107292743 endingPage "1524" @default.
• W107292743 startingPage "1524" @default.
• W107292743 abstract "Editor—I agree with Wort and Rogers that current British guidelines on community acquired pneumonia need revision, but I do not believe that the addition of erythromycin should always be considered in elderly people.1They cite, as the basis for this recommendation, a study from Israel in which serological evidence of Chlamydia pneumoniae was found in 26% of cases of community acquired pneumonia in elderly people.2 It is not clear, in this or other similar studies, whether serological detection of C pneumoniae indicates the cause of the pneumonia or whether treatment directed against it will make a clinical difference. More than one pathogen was identified in 30.4% (age 65-74) and 37.8% (age ⩾75) of cases, but further details are not given. In the original publication other pathogens were also identified in the majority (69%) of cases in which C pneumoniae was found (Streptococcus pneumoniae in 55%).3A high frequency of copathogens has been found in similar studies, suggesting that C pneumoniae may simply initiate events while the other pathogen causes the pneumonia. Treatment with antibiotics to which C pneumoniae is not sensitive leads to clinical recovery as quickly as when agents to which it is sensitive are given,4 supporting this viewpoint. A recent North American study, which included elderly patients, argued that there is no place for routine use of macrolides since only 7.5% of patients were found to have an organism that merited macrolide treatment and none of these patients died.5 Other pathogens for which a macrolide is first line treatment have been uncommon in other studies of community acquired pneumonia in elderly people. Disadvantages of concurrent macrolide treatment might include gastrointestinal and other side effects, drug interactions (for example, with theophylline), cost, and the development of macrolide resistance—already, in the United Kingdom, higher in the pneumococcus than for penicillins at 8.6% of isolates.What is currently lacking most of all is evidence of the frequency of C pneumoniae as a cause of community acquired pneumonia requiring specific treatment. No reliable data exist on the frequency of C pneumoniae in the United Kingdom. Before recommending a macrolide in elderly people with community acquired pneumonia I would like to see a randomised controlled trial of β lactam alone versus β lactam plus macrolide. Until such data are available I suggest that macrolides should be used initially only in severely ill people (in combination with a β lactam), especially when legionella infection is suspected." @default.
• W107292743 created "2016-06-24" @default.
• W107292743 creator A5007989046 @default.
• W107292743 date "1998-11-28" @default.
• W107292743 modified "2023-09-24" @default.
• W107292743 title "Community acquired pneumonia in elderly people" @default.
• W107292743 cites W1488746339 @default.
• W107292743 cites W1982448191 @default.
• W107292743 cites W2061138085 @default.
• W107292743 cites W2100333537 @default.
• W107292743 cites W2140586996 @default.
• W107292743 cites W2143017101 @default.
• W107292743 cites W2148477637 @default.
• W107292743 cites W2265777460 @default.
• W107292743 cites W4290746977 @default.
• W107292743 cites W4300500969 @default.
• W107292743 doi "https://doi.org/10.1136/bmj.317.7171.1524a" @default.
• W107292743 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1114353" @default.
• W107292743 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9831595" @default.
• W107292743 hasPublicationYear "1998" @default.
• W107292743 type Work @default.
• W107292743 sameAs 107292743 @default.
• W107292743 citedByCount "5" @default.
• W107292743 countsByYear W1072927432013 @default.
• W107292743 crossrefType "journal-article" @default.
• W107292743 hasAuthorship W107292743A5007989046 @default.
• W107292743 hasBestOaLocation W1072927432 @default.
• W107292743 hasConcept C126322002 @default.
• W107292743 hasConcept C136764020 @default.
• W107292743 hasConcept C177713679 @default.
• W107292743 hasConcept C2522767166 @default.
• W107292743 hasConcept C2776102371 @default.
• W107292743 hasConcept C2777914695 @default.
• W107292743 hasConcept C41008148 @default.
• W107292743 hasConcept C71924100 @default.
• W107292743 hasConcept C74909509 @default.
• W107292743 hasConceptScore W107292743C126322002 @default.
• W107292743 hasConceptScore W107292743C136764020 @default.
• W107292743 hasConceptScore W107292743C177713679 @default.
• W107292743 hasConceptScore W107292743C2522767166 @default.
• W107292743 hasConceptScore W107292743C2776102371 @default.
• W107292743 hasConceptScore W107292743C2777914695 @default.
• W107292743 hasConceptScore W107292743C41008148 @default.
• W107292743 hasConceptScore W107292743C71924100 @default.
• W107292743 hasConceptScore W107292743C74909509 @default.
• W107292743 hasIssue "7171" @default.
• W107292743 hasLocation W1072927431 @default.
• W107292743 hasLocation W1072927432 @default.
• W107292743 hasLocation W1072927433 @default.
• W107292743 hasLocation W1072927434 @default.
• W107292743 hasOpenAccess W107292743 @default.
• W107292743 hasPrimaryLocation W1072927431 @default.
• W107292743 hasRelatedWork W1595725943 @default.
• W107292743 hasRelatedWork W2091798965 @default.
• W107292743 hasRelatedWork W2352908562 @default.
• W107292743 hasRelatedWork W2422225883 @default.
• W107292743 hasRelatedWork W2748952813 @default.
• W107292743 hasRelatedWork W2789466320 @default.
• W107292743 hasRelatedWork W3009231746 @default.
• W107292743 hasRelatedWork W3031993251 @default.
• W107292743 hasRelatedWork W3102227035 @default.
• W107292743 hasRelatedWork W4311479006 @default.
• W107292743 hasVolume "317" @default.
• W107292743 isParatext "false" @default.
• W107292743 isRetracted "false" @default.
• W107292743 magId "107292743" @default.
• W107292743 workType "article" @default.